Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Rottenberg

Showing results (91-100 of 122) with videos related to

Pageof 13
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsSven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Oncogene|December 17, 2025
MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumorsHülya Dogan, Martin Liptay, Joana S Barbosa, et al.
Cancer Research Communications|December 5, 2022
Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacyCarmen A Widmer, Ismar Klebic, Natalya Domanitskaya, et al.
Cancer Research|August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical ModelsLenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Biorxiv : the Preprint Server for Biology|August 2, 2024
Deep Learning-based Modeling for Preclinical Drug Safety AssessmentGuillaume Jaume, Simone de Brot, Andrew H Song, et al.
British Journal of Cancer|June 12, 2024
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)S Lot Aronson, Cédric Walker, Bram Thijssen, et al.
The EMBO Journal|November 5, 2015
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugsRosa Planells-Cases, Darius Lutter, Charlotte Guyader, et al.
Molecular Cell|January 18, 2016
HELB Is a Feedback Inhibitor of DNA End ResectionJán Tkáč, Guotai Xu, Hemanta Adhikary, et al.
Cancer Research|July 16, 2010
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistanceNatalia Issaeva, Huw D Thomas, Tatjana Djureinovic, et al.
Cell Reports|August 27, 2020
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End JoiningPaola Francica, Merve Mutlu, Vincent A Blomen, et al.
Pageof 13

Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2008
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsSven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, et al.
Oncogene|December 17, 2025
MDC1 counteracts replication fork reversal and mediates chemosensitivity in BRCA1/2-deficient tumorsHülya Dogan, Martin Liptay, Joana S Barbosa, et al.
Cancer Research Communications|December 5, 2022
Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacyCarmen A Widmer, Ismar Klebic, Natalya Domanitskaya, et al.
Cancer Research|August 24, 2016
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical ModelsLenka Oplustil O'Connor, Stuart L Rulten, Aaron N Cranston, et al.
Biorxiv : the Preprint Server for Biology|August 2, 2024
Deep Learning-based Modeling for Preclinical Drug Safety AssessmentGuillaume Jaume, Simone de Brot, Andrew H Song, et al.
British Journal of Cancer|June 12, 2024
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)S Lot Aronson, Cédric Walker, Bram Thijssen, et al.
The EMBO Journal|November 5, 2015
Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugsRosa Planells-Cases, Darius Lutter, Charlotte Guyader, et al.
Molecular Cell|January 18, 2016
HELB Is a Feedback Inhibitor of DNA End ResectionJán Tkáč, Guotai Xu, Hemanta Adhikary, et al.
Cancer Research|July 16, 2010
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistanceNatalia Issaeva, Huw D Thomas, Tatjana Djureinovic, et al.
Cell Reports|August 27, 2020
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End JoiningPaola Francica, Merve Mutlu, Vincent A Blomen, et al.
Pageof 13